LeonaBio

LeonaBio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of LeonaBio (LONA) as of Nov 5, 2026 is 43.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 100.27 % — a change of -56.82% (lower).

FCF Conversion

43.30 %

YoY

-56.82%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of LeonaBio is 2025 43.30 % . FCF Conversion Rate (FCF/EBITDA) of LeonaBio was 2024 100.27 % . It decreases by -56.82% lower compared to the previous year.

The LeonaBio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
87.95 USD
Jan 1, 2019
71.94 USD
Jan 1, 2020
132.46 USD
Jan 1, 2021
81.44 USD
Jan 1, 2022
76.97 USD
Jan 1, 2023
85.88 USD
Jan 1, 2024
100.27 USD
Jan 1, 2025
43.30 USD
The LeonaBio FCF Conversion history
YEARFCF ConversionYoY
43.30 %-56.82%
100.27 %+16.76%
85.88 %+11.58%
76.97 %-5.49%
81.44 %-38.52%
132.46 %+84.12%
71.94 %-18.20%
87.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

FCF Conversion Rate (FCF/EBITDA) of LeonaBio is 43.30 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of LeonaBio changed from 100.27 % to 43.30 %, representing a -56.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s LeonaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — LeonaBio

All Key Metrics — LeonaBio